Daxor announces expert recomendations on use of blood volume analysis

Daxor Corporation announces that experts recommend the use of blood volume analysis to guide optimal treatment in heart failure patient at two Scientific Sessions held during the Heart Failure Society of America Annual Scientific Meeting on October 8th & 9th, 2023, at the Huntington Convention Center in Cleveland, OH. Highlights from the sessions included: Expert panelists from Duke Clinical Health, the Mayo Clinic, and Medstar Hospital system all presented case studies and peer-reviewed data showing BVA to be an essential diagnostic tool for their practice. BVA was identified as a unique tool to determine intravascular volume profiles, guiding the most appropriate individualized patient management. Implementing BVA led to improved patient outcomes, decreases in hospital length of stay, and provided positive return on investment for panelists sharing their clinical experience. Daxor’s technology was also featured in an expert panel on Innovative Devices for Heart Failure Management highlighting the added benefit that it is now available and cleared for use by FDA Historically, clinicians have made care decisions based on proxy pressure-based hemodynamics assessments, but data show pressure is often a poor proxy for volume, and optimal volume care is the cornerstone of effective heart failure congestion care. The first session, titled, “Managing Congestion: Targeting Pressure vs. Volume,” was co-moderated by Dr. Arvind Bhimaraj, Houston Methodist DeBakey Heart and Vascular and Dr. Marat Fudim, Duke University Health. Panel members including Dr. Wayne Miller, Mayo Clinic, Dr. Brian Howard, Wellstar, and Stephanie Barnes, CHFN, Duke University Hospital all called for the routine use of BVA to improve heart failure care. Dr. Miller stated, “If you don’t measure, you don’t know volume.” Dr. Miller also highlighted the importance of knowing the red blood cell volume to optimize fluid management which is a key metric of Daxor’s BVA diagnostic blood test. Clinical use of blood volume analysis was highlighted through patient case studies presented by Dr. Howard and Stephanie Barnes. Dr. Howard conveyed, “BVA is appropriate for both inpatient and outpatient use when volume status is unclear, the patient has worsening renal function, to improve heart failure outcomes, and when you need more information than what physical exam or labs provide.” Stephanie Barnes added, “Implementing BVA improves patient outcomes, decreases hospital length of stay, and is a wonderful return on investment.” The second session, titled, “Device Innovation to Manage Congestion in Heart Failure,” discussed the latest methods to recognize and treat congestion in heart failure. Panel member Dr. Maria Rosa Constanzo, Midwest Cardiovascular Institute, stated, “assessment of congestion is complex,” and stressed the importance of monitoring congestion early before hospitalization. Dr. Costanzo added, “BVA is helpful and gives you total blood, red blood cell, plasma volume so you can phenotype the patient’s volume status in a more precise way.”